肿瘤细胞治疗研究
英文原题：Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells.
Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells.
靶向 CD20 的嵌合抗原受体（CAR）CAR-T 细胞疗法可能成为 B 细胞恶性肿瘤犬患者的一种新型过继细胞疗法。
靶向CD20的嵌合抗原受体（CAR）T细胞疗法可能成为治疗犬B细胞恶性肿瘤的新型过继细胞疗法。体内注射CAR-T细胞后，监测外周循环中的CAR-T细胞对于确认其在体内持久存续至关重要。本研究开发了一种针对犬CD20 CAR的新型单克隆抗体，其单链可变片段来源于我们此前报道的抗犬CD20治疗性抗体。此外，在一项安全性研究中，健康比格犬注射该治疗性抗体后，本研究的单克隆抗体能够检测其血清中的抗犬CD20治疗性嵌合抗体。该单克隆抗体可用于监测犬CD20-CAR-T细胞以及犬淋巴瘤治疗中使用的抗犬CD20治疗性抗体。
Chimeric antigen receptor (CAR) CAR-T cell therapy targeting CD20 can be a novel adoptive cell therapy for canine patients with B-cell malignancy. After injection of the CAR-T cells in vivo, monitoring circulating CAR-T cells is essential to prove in vivo persistence of CAR-T cells. In this study, we developed a novel monoclonal antibody against canine CD20 CAR, whose single-chain variable fragment was derived from the our previously reported anti-canine CD20 therapeutic antibody. Furthermore, we proved that this monoclonal antibody can detect therapeutic anti-canine CD20 chimeric antibody in the serum from healthy beagle dogs injected with the therapeutic antibody for safety study. This monoclonal antibody is a useful tool for monitoring both canine CD20-CAR-T cells and anti-canine CD20 therapeutic antibody for canine lymphoma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
